SCHEMBL760372

SCHEMBL760372

Nc1cc(Br)c2[nH]ncc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.50
MAPT P10636 4/20 0.46
ROCK1 Q13464 3/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 2/20 0.46
ROCK2 O75116 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PKM P14618 1/20 0.41
HTT P42858 1/20 0.41
CHEK1 O14757 3/20 0.39
METAP2 P50579 2/20 0.37
DYRK1A Q13627 2/20 0.37
CSNK2A1 P68400 1/20 0.37
AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11577531 0.79 NOS1 (0.53) NOS1MAPTKDM4EMEN1KMT2A
SCHEMBL2425031 0.78 NOS1 (0.52) NOS1MAPTCHEK1METAP2DYRK1A
SCHEMBL1286200 0.76 MAPT (0.52) NOS1MAPTROCK1KDM4EMEN1
SCHEMBL759126 0.76 NOS1 (0.50) NOS1MAPTROCK1KDM4EMEN1
SCHEMBL3515094 0.76 MAPT (0.46) NOS1MAPTROCK1KDM4EMEN1
SCHEMBL30099420 0.76 NOS1 (0.50) NOS1MAPTCHEK1METAP2DYRK1A
SCHEMBL2430496 0.76 NOS1 (0.50) NOS1MAPTMEN1KMT2ACHEK1
SCHEMBL14500106 0.76 NOS1 (0.50) NOS1MAPTKDM4EALDH1A1HTT
Hydrochloric Acid SCHEMBL15517276 0.74 MAPT (0.50) MAPTROCK1KDM4EMEN1KMT2A
SCHEMBL25475118 0.73 KDM4E (0.43) MAPTROCK1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 US disclosed
WO-2025133191-A1 NOVEL SULFONAMIDES OR SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2025-06-26 WO disclosed
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators RAPPORT THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-19 US disclosed
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-12 US disclosed
CN-118496159-B Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect 广州医科大学附属市八医院 2024-09-24 CN disclosed
CN-118496159-A Application of compound in preparation of medicine with liver fibrosis preventing and/or treating effect 广州医科大学附属市八医院 2024-08-16 CN disclosed
US-20230114165-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-04-13 US disclosed
US-20230110576-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-04-13 US disclosed
EP-4144736-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-03-08 EP disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
EP-2001480-A2 INDAZOLE COMPOUNDS Abbott Laboratories (US) 2008-12-17 EP disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 NOS1 849/4885MAPT 2375/4885ROCK1 2438/4885
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885
US-20230110576-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 NOS1 900/4885MAPT 3755/4885ROCK1 398/4885
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885
US-20230114165-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A NOS1 530/4885MAPT 2655/4885ROCK1 4034/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A NOS1 498/4885MAPT 2649/4885ROCK1 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.